Combined germline variations of thrombophilic genes promote genesis of lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5449-5454

  Ozen, Filiz ^a   Polat, Fikriye ^b   Arslan, Sulhattin ^a   Ozdemir, Oztürk ^a,c  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

A case control study; Combined thrombophilic genes; Germ line variations; Lung cancer

Indexed keywords

ACE PROTEIN, HUMAN; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; DIPEPTIDYL CARBOXYPEPTIDASE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PROGNOSIS; RISK FACTOR; THROMBOPHILIA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RISK FACTORS; THROMBOPHILIA; TUMOR MARKERS, BIOLOGICAL;

EID: 84887605283     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5449     Document Type: Article

References (40)

1. Alberola V, Sarries C, Rosell R, et al (2004). Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin Lung Cancer, 5, 360-5.
2. Arslan S, Karadayi S, Yildirim ME, et al (2011). The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep, 38, 991-6.
3. Bakan N, Bakan E, Süerdem M, et al (1988). Serum zinc and angiotensin-converting enzyme levels in patients with lung cancer. Biofactors, 1, 177-8.
4. Bennet AM, Di Angelantonio E, Ye Z, et al (2007). Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA, 298, 1300-11.
5. Blom JW, Doggen CJ, Osanto S, et al (2005). Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293, 715-22.
6. Brüggemann LW, Versteeg HH, Niers TM, et al (2008). Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med, 12, 2622-7.
7. Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J (2004). Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis. Int J Mol Med, 13, 759-66.
8. Couraud S, Zalcman G, Milleron B, et al (2012). Lung cancer in never smokers--a review. Eur J Cancer, 48, 1299-311.
9. Cui LH, Shin MH, Kim HN, et al (2011). Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population. BMC Med Genetics, 12, 28.
10. Cui LH, Yu Z, Zhang TT, et al (2011). Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics, 12, 797-808.
11. Dahlback B (2008). Advances in understanding pathogenic mechanisms of thrombophilic disorders. BLOOD, 112, 19-27.
12. Devic-Pavlic S, Ristic S, Flego V, et al (2012). Angiotensin-converting enzyme insertion/deletion gene polymorphism in lung cancer patients. Genet Test Mol Biomarkers, 16, 722-5.
13. Feng Y, Ni L, Wan H, et al (2011). Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep, 26, 1157-64.
14. Gao S, Liu N, Ma Y, et al (2012). Methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers in ovarian cancer risk. Asian Pac J Cancer Prev, 13, 569-73.
15. Gao M, Wang Y, Shi Y, et al (2012). The relationship between three well-characterized polymorphisms of the angiotensin converting enzyme gene and lung cancer risk: a case-control study and a meta-analysis. J Renin Angiotensin Aldosterone Syst, 13, 455-60.
16. Kiyohara C, Horiuchi T, Takayama K, et al (2011). Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population. BMC Cancer, 11, 459.
17. Lam TK, Rotunno M, Ryan BM, et al (2013). Heme-related gene expression signatures of meat intakes in lung cancer tissues. Mol Carcinog, [Epub ahead of print].
18. Lee MS, Asomaning K, Su L, et al (2012). MTHFR polymorphisms, folate intake and carcinogen DNA adducts in the lung. Int J Cancer, 131, 1203-9.
19. Li CH, Cai L, Chen XS, et al (2008). DDP-sensitivity-related genes in 10 lung cancer cell lines. Zhonghua Zhong Liu Za Zhi, 30, 418-21.
20. Liu CS, Tsai CW, Hsia TC, et al (2009). Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics and Proteomics, 6, 325-30.
21. Nacak M, Nacak I, Sanli M, et al (2010). Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer Genetics and Cytogenetics, 198, 22-6.
22. Offersen BV, Pfeiffer P, Andreasen P, et al (2007). Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer, 56, 43-50.
23. Onitilo AA, Doi SA, Engel JM, et al (2013). Relationship between Factor V Leiden mutation and venous thromboembolism in patients with breast cancer treated with tamoxifen. Thromb Res, 131, 567-8.
24. Pavey SJ, Marsh NA, Ray MJ, et al (1996). Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. Boll Soc Ital Biol Sper, 72, 331-40.
25. Prasad VV, Wilkhoo H, (2011). Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie, 34, 422-6.
26. Shetty S, Idell S, (2000). Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol Lung Cell Mol Physiol, 278, 148-56.
27. Shetty S, Shetty P, Idell S, et al (2008). Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem, 283, 19570-80.
28. Siemianowicz K, Gminski J, Garczorz W, et al (2003). Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep, 10, 1341-4.
29. Stankova J, Shang J, Rozen R (2005). Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res, 11, 2047-52.
30. Su WP, Chen YT, Lai WW et al (2011). Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer, 71, 28-33.
31. Thu KL, Vucic EA, Chari R, et al (2012). Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. CoPLoS One, 7, 33003.
32. Truong T, Sauter W, McKay JD, et al (2010). International lung cancer consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis, 31, 625-33.
33. Tug E, Aydin H, Kaplan E, et al (2011). Frequency of genetic mutations associated with thromboembolism in the Western Black Sea region. Intern Med, 50, 17-21.
34. Vaissière T, Hung RJ, Zaridze D, et al (2009). Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res, 69, 243-52.
35. Werle B, Kotzsch M, Lah TT, et al (2004). Plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res, 24, 4147-61.
36. Yaren A, Öztop I, Turgut S, et al (2008). Angiotensin-converting small-cell lung cancer. Experimental Biol Med, 233, 32-7.
37. Yenicesu GI, Cetin M, Ozdemir O, et al (2010). A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reproductive Immunol, 63, 126-36.
38. Zaatari GS, Otrock ZK, Sabbagh AS, et al (2006). Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathol, 38, 442-4.
39. Zekanowska E, Cieslinski K, Rość D (2004). Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer. Pneumonol Alergol Pol, 72, 409-14.
40. Zhang Y, Chen GQ, Ji Y, et al (2012). Ouantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep, 39, 6203-11.